Post-earnings recap
Reported
Wed, Nov 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics is still in a developmental phase, with no revenue reported and a significant loss per share. The stock reaction of a 1.05% decline suggests that investors may have been expecting more clarity on financial performance or future guidance. The lack of specific metrics and updates may lead to continued uncertainty in the market.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized the importance of their ongoing research and development efforts. They did not provide detailed financial guidance, reflecting a cautious approach.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline and clinical trials.